Navigation Links
Bedford Laboratories(TM) First To Manufacture Generic Indomethacin for Injection USP
Date:2/16/2010

BEDFORD, Ohio, Feb. 16 /PRNewswire/ -- Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., a provider of select specialty injectables, is pleased to announce the addition of Indomethacin for Injection to its existing product line.  This product is AP rated and is equivalent to Indocin® by Lundbeck, Inc. Indomethacin for Injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective.  Clear-cut clinical evidence of a hemodynamically significant patent ductus arteriosus should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly and pulmonary plethora on chest x-ray.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO)

Bedford Laboratories will supply Indomethacin for Injection USP as single dose vials containing indomethacin sodium, equivalent to 1 mg indomethacin.  "We are very excited and pleased to announce the launch of this critical product.  The release of this product to the market place is very timely, given that the innovator product is currently on long-term backorder (source: www.fda.gov). This is a great milestone for Bedford Laboratories and we are very proud to add this product to our growing portfolio," said David Gaugh, Vice President and General Manager, Bedford Laboratories.

Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169, or from the company's web site, www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products offering a broad range of multisource injectables across multiple therapeutic classes. Bedford Laboratories is one of the largest generic injectable pharmaceutical companies in the US.

Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc. For more information on Bedford Laboratories, visit www.bedfordlabs.com.

About Ben Venue Laboratories, Inc.

Ben Venue Laboratories, Inc. was founded in 1938 and is a leading contract manufacturer of highly complex, sterile injectable drug products for the global pharmaceutical industry. Ben Venue has been under contract with the National Cancer Institute since 1967 to develop parenteral dosage forms for many anticancer agents. It has also manufactured various AIDS-specific drugs in conjunction with the NCI. Ben Venue employs more than 1,300 people.  For more information on Ben Venue Laboratories and current career opportunities, visit www.benvenue.com.

Ben Venue is a U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies (Ingelheim, Germany). For more information, please visit http://us.boehringer-ingelheim.com.

Indocin® is a registered trademark of Lundbeck, Inc.

SOURCE Bedford Laboratories

RELATED LINKS
http://www.bedfordlabs.com

'/>"/>

SOURCE Bedford Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
4. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Tainted Chinese Food Ingredients First Discovered in 2005
9. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Period October – December 2016 Revenues amounted ... -16.4 (-6.4) million Result after tax amounted to SEK -16.3 ... Cash flow from operating activities amounted to SEK -8.3 (-7.3) ... Period full year 2016 ... Operating result amounted to SEK -39.5 (-29.5) million Result ...
(Date:2/24/2017)... YORK , February 24, 2017 Following ... Israel , s AMAR ... $ 250 M w ound care market ... s BST for inclusion in the ... healthcare reimbursement system   E-QURE Corp. (OTCQB: ...
(Date:2/24/2017)... -- Research and Markets has announced the addition of the ... 2025" report to their offering. ... The Global Empty Capsules Market is poised to grow at ... $2.9 billion by 2025. This industry report analyzes the ... well as regional levels presented in the research scope. The study provides ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide exposure ... a specific LRRK2 mutation, according to a study released today at the 1st ... of a link between pesticides and incidence of sporadic PD through occupational exposure. ...
(Date:2/24/2017)... ... 24, 2017 , ... HealthPostures, expert standing desk solution designer, ... built into the home office sit stand solution are bold colors, a new ... the benefits embedded in the TaskMate Go are available 24/7 through HealthPostures' online ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official release ... show in Cannes (France), XO Private has initiated a second print-run of its lavish ... almost a metre across when open, weighs in at more than six kilos, retails ...
(Date:2/24/2017)... ... ... An in-depth computational analysis of genetic variants implicated in both schizophrenia and rheumatoid ... explain why susceptibility to one of the disorders could place individuals at lower risk ... journal npj Schizophrenia. , “There is a wealth of genomic data on both ...
(Date:2/24/2017)... ... ... The Smart Machine Age is here, and it’s disrupting everything. Not only could it ... the United States may be taken over by technology in the next five to ... over colleagues is drawing to a close. Success will belong to those who can ...
Breaking Medicine News(10 mins):